Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 435 participants.

Also called NCT01059799

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 435 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01059799
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Hong Kong SAR China, Japan, Malaysia, South Korea, Taiwan, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01059799. Randomized; no masking; primary purpose treatment. Start 2010-02-01 (actual); primary completion 2010-12-16 (actual). Results posted on 2015-11-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Acronym
BEGIN™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01059799
Content hash
51fff53ae5cd533fe0f9fce07518844f4359178d918909bb96d631a4be39c2d9